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The lack of an official-stage classification system for thymic malig-
nancies is an issue that hampers progress in this rare disease. A collab-
orative effort by the International Association for the Study of Lung 
Cancer and the International Thymic Malignancies Interest Group is 
underway to develop proposals for such a system. A database of more 
than 10,000 cases worldwide has been assembled to provide a solid 
basis for analysis. This report outlines the structure of the effort and 
the process that has been designed.
Key Words: Thymoma, Thymic carcinoma, Staging of stage 
classification.
(J Thorac Oncol. 2013;8: 1467–1473)
Thymic malignancies are relatively rare and are therefore classified as an orphan disease. Among many issues ham-
pering the ability to make robust scientific progress is the fact 
that there is no official American Joint Committee on Cancer/
Union for International Cancer Control (AJCC/UICC) stage 
classification for these tumors. The ability to describe the 
extent of disease through a consistent universal nomenclature 
is a fundamental requirement for comparison of clinical results 
between centers and for multi-institutional collaborative work.
At least 15 different stage classification systems have 
been proposed, beginning as far back as 1978. A review of the 
various classification systems and their differences is the sub-
ject of a recent article.1 The most widely known system, the 
Masaoka system, was proposed in 1981 on the basis of an expe-
rience with 91 patients.2 All of the other proposed systems have 
involved roughly similar, relatively small cohorts of patients.1,3–5
Although the Masaoka system and variations thereof like 
Masaoka-Koga6 have been what has been used most widely, in 
fact there are significant discrepancies between centers regard-
ing how the relatively vague wording describing the stages is 
interpreted. Thus, not only is the lack of an official system a 
problem but also the lack of clear definitions and consistent 
application even when using the same system.
To at least address the issue of vague wording and incon-
sistent interpretation, the International Thymic Malignancies 
Interest Group (ITMIG) assembled an international team that 
proposed clarifications of the definitions of the Masaoka-Koga 
classification.7 This was endorsed by the vast majority of clini-
cians active in this disease as a standard to use going forward. 
Nevertheless, this represents merely a consensus regarding a 
clarification of heretofore vague wording of an existing stage 
classification system. In fact, the explicit task of the ITMIG 
effort was to not make any changes to the Masaoka-Koga sys-
tem, and not to address whether the system is appropriate, but 
only to achieve greater consistency by applying a uniform con-
sensus interpretation.
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International Association for the Study of Lung Cancer 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/13/0812-1467
The IASLC/ITMIG Thymic Malignancies Staging Project
Development of a Stage Classification for Thymic Malignancies
Frank C. Detterbeck, MD,* Hisao Asamura, MD,† John Crowley, PhD,‡ Conrad Falkson, MBChB,§ 
Giuseppe Giaccone, MD,║ Dori Giroux, MS,‡ James Huang, MD,¶ Jhingook Kim, MD,#  
Kazuya Kondo, MD,** Marco Lucchi, MD,†† Mirella Marino, MD,‡‡ Edith M. Marom, MD,§§  
Andrew Nicholson, MD,║║ Meinoshin Okumura, MD,¶¶ Enrico Ruffini, MD,##  
Paul van Schil, MD,*** Kelly Stratton, MS,‡ on behalf of the Staging and Prognostic Factors Committee,††† 
Members of the Advisory Boards,‡‡‡ and Participating Institutions of the Thymic Domain§§§
*Department of Thoracic Surgery, Yale New Haven Hospital, Yale University 
School of Medicine, New Haven, Connecticut; †Thoracic Surgery, 
National Cancer Center Hospital, Tokyo, Japan; ‡Biostatistics, Cancer 
Research And Biostatistics, Seattle, Washington; §Radiation Oncology, 
Queen’s University, Ontario, Canada; ║Medical Oncology, National 
Cancer Institute, Bethesda, Maryland; ¶Thoracic Surgery, Sloan-Kettering 
Cancer Center, New York, New York; #Thoracic Surgery, Samsung Medical 
Center, Seoul, South Korea; **Thoracic Surgery, University of Tokushima, 
Tokushima, Japan; ††Thoracic Surgery, University of Pisa, Pisa, Italy; 
‡‡Pathology, Regina Elena National Cancer Institute, Rome, Italy; 
§§Radiology, MD Anderson Cancer Center, Houston, Texas; ║║Pathology, 
Royal Brompton Hospital, London, United Kingdom; ¶¶Thoracic Surgery, 
Osaka University, Osaka, Japan; ##Thoracic Surgery, University of Torino, 
Torino, Italy; ***Thoracic Surgery, Antwerp University Hospital, Antwerp, 
Belgium; ††† Members of the Staging and Prognostic Factors Committee 
are listed in the Appendix 1; ‡‡‡ Members of the Advisory Boards are 
listed in the Appendices 2, 3, and 4; and §§§ Members of the Participating 
Institutions of the Thymic Domain are listed in the Appendix 5.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Frank C. Detterbeck, MD, Department of 
Surgery, Division of Thoracic Surgery, Yale University School of 
Medicine, BB2 333 Cedar Street, New Haven, Connecticut 06510. 
E-mail: frank.detterbeck@yale.edu
IASLC STAGING COMMITTEE ARTICLE
1468 Copyright © 2013 by the International Association for the Study of Lung Cancer
Detterbeck et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013
(IASLC) more or less independently and simultaneously set 
out to accomplish this, and then joined forces in 2010, with 
ITMIG providing the engagement of the vast majority of 
clinicians active in this disease and IASLC providing infra-
structure and experience gained during the development of the 
seventh edition of the lung cancer stage classification.
The current lung cancer stage classification was led by 
a massive IASLC initiative that assembled an international 
database of more than 100,000 patients with lung cancer 
diagnosed in a defined 10-year span.8 In contrast, the previ-
ous classification system was based on approximately 5000 
patients diagnosed over more than a 30-year span. IASLC led 
an extensive internal and external validation of the stage pro-
posals, which was carried out by the Cancer Research And 
Biostatistics (CRAB) organization.9 The IASLC proposals 
formed the basis of the AJCC/UICC seventh edition lung can-
cer stage classification system. IASLC and CRAB are now 
providing their expertise to the development of a thymic stage 
classification system.
IASLC and ITMIG partnered to create a Thymic 
Malignancies Domain of the Staging and Prognostic Factors 
Committee (SPFC-TD), which is charged with the develop-
ment of proposals for change to AJCC/UICC for the eighth 
edition of the stage classification system. Individuals were 
invited to participate in the SPFC-TD, based on expertise and 
interest. The members of the SPFC-TD are shown in Table 1.
Creation of a Database
To allow global collaboration in clinical science regard-
ing thymic malignancies, ITMIG created a retrospective and a 
prospective database. Institutions were invited to participate; 
the overwhelming response is a testament to the worldwide 
engagement and culture of collaboration that ITMIG has 
achieved.
Among the initial uses of this database is the stage clas-
sification initiative. ITMIG assembled a retrospective global 
database of 6097 cases. The Japanese Association for Research 
in the Thymus also assembled a database of 2897 cases, and 
made this available to ITMIG for the stage classification proj-
ect. Together this represents a retrospective database of 8994 
cases from 77 centers in 16 countries. This retrospective data-
base was cleaned and provided to CRAB; an additional 1814 
cases were contributed by the European Society of Thoracic 
Surgeons thymic group directly to CRAB. Thus, the total 
sample size available for analysis by CRAB includes 10,808 
patients with thymic malignancies from 105 sites worldwide. 
A map of participating centers is shown in Figure 1.
The retrospective database has some limitations, which 
include the amount of detail that is available, varying inter-
pretations of how a particular dataelement is defined by dif-
ferent institutions, changing definitions and policies over the 
course of the data collection, and questions about the com-
parability of data from different centers despite bearing the 
same data labels. ITMIG has also launched a prospective 
database, which is based on clear definitions developed by 
an international consensus, and contains many details that 
should provide another quantum leap forward over the already 
impressive retrospective database. The timing of the AJCC/
UICC, however, limits the availability of sufficient prospec-
tive data to substantially contribute to the eighth edition of the 
stage classification.
Characteristics of a Thymic Stage 
Classification System
The SPFC-TD thought that a thymic stage classifica-
tion should ideally have several characteristics (Table 2). First 
of all, the stage classification should be a nomenclature that 
describes the anatomic extent of disease only. Other factors 
that contribute to prognosis will be included in a prognostic 
prediction model but will not be a part of the stage classi-
fication (see later discussion of prognostic factors). This is 
consistent with the primary purpose of stage classification. 
This also recognizes the inherent complexity of prediction of 
prognosis and the inherent fundamental differences between 
an anatomic extent of disease classification and prognosti-
cation.10 Classification of the anatomic disease is concrete, 
grounded in actual findings that can be applied to an individ-
ual patient. Prediction of prognosis is inherently speculative, 
multifactorial (including factors that cannot be assessed at 
the time), dynamic and fluid, and applies to a patient popula-
tion. Prognostication is inherently associated with uncertainty, 
which becomes greater and greater as one moves closer to pre-
dicting prognosis for an individual.
The thymic stage classification system should ideally 
apply to all types of thymic malignancies, e.g., thymoma, 
thymic carcinoma, and thymic carcinoid tumors. A strong 
argument for this position is the simplicity of having only 
one system, which is particularly important in a rare disease 
that is encountered by many clinicians only sporadically. 
Furthermore, there are grey areas in the distinction between 
some histologic types,11 and this is especially true when only 
limited biopsy material is available such as in the clinical 
(pretreatment) phase of stage classification. It can be argued 
that the behavior of different types of thymic tumors is dispa-
rate, but there is precedent for a stage classification system to 
nevertheless be applicable (e.g., consider that the lung stage 
classification system is validated for small-cell lung cancer, 
non–small-cell lung cancer, and lung carcinoid tumors).12,13
The SPFC-TD thinks that it would be best to conform to 
a T (tumor), N (node), and M (metastasis) structure, which is 
used for the vast majority of malignancies (although there are 
exceptions). A tumor, node, metastasis–based system is more 
likely to be applicable to all thymic malignancies. Furthermore, 
node involvement may be more relevant, even for thymoma, 
than has been appreciated. A recent report involving node dis-
section found nodal metastases in 29% of stage III thymomas 
(thymic carcinoma was excluded).14 Although node involve-
ment is traditionally thought to be rare with thymoma, a careful 
node assessment has generally not been carried out.
Guiding Principles for the Development 
of the Stage Classification System
What criteria should be used to establish a particu-
lar point as a good boundary between T, N, and M classes 
or between stage groupings? It is possible to consider 
many different arguments, and how much weight is given 
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to a particular argument is influenced by the nature of the 
tumor, characteristics of the data available, and the primary 
purpose of the stage classification system. The SPFC-TD 
decided on a series of guiding principles, which are sum-
marized in Table 2.
A fundamental goal of a classification system is to be 
able to consistently classify patients at many centers. If the 
classification system cannot be applied consistently, none 
of the other considerations will make up for this funda-
mental deficiency. ITMIG is launching studies of intra- and 
TABLE 1.  Members of the Thymic Malignancies Domain of the IASLC Staging and Prognostic Factors Committee and 
Members of Its Advisory Board
Name Specialty Institution Location
F. Detterbeck, Chair Thoracic Surgery Yale University New Haven, CT
Hisao Asamura Thoracic Surgery National Cancer Center Hospital Tokyo, Japan
John Crowley Biostatistics Cancer Research And Biostatistics Seattle, WA
Dori Giroux Biostatistics Cancer Research And Biostatistics Seattle, WA
James Huang Thoracic Surgery Sloan-Kettering Cancer Center New York, NY
Jhingook Kim Thoracic Surgery Samsung Medical Center Seoul, South Korea
Mirella Marino Pathology Regina Elena National Cancer Institute Rome, Italy
Edith Marom Radiology MD Anderson Cancer Center Houston, TX
Alan Mitchell Biostatistics Cancer Research And Biostatistics Seattle, WA
Andrew Nicholson Pathology Royal Brompton Hospital London, United Kingdom
Enrico Ruffini Thoracic Surgery University of Torino Torino, Italy
Paul van Schil Thoracic Surgery Antwerp University Hospital Antwerp, Belgium
Advisory Board
  Conrad Falkson Radiation Oncology Queen’s University Ontario, Canada
  Giuseppe Giaccone Medical Oncology National Cancer Institute Bethesda, MD
  Kazuya Kondo Thoracic Surgery University of Tokushima Tokushima, Japan
  Marco Lucchi Thoracic Surgery University of Pisa Pisa, Italy
  Meinoshin Okumura Thoracic Surgery Osaka University Osaka, Japan
 Pier Luigi Filosso Thoracic Surgery University of Torino Torino, Italy
IASLC, International Association for the Study of Lung Cancer.
FIGURE 1.  Map of Centers contributing to the Staging Project database.
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interobserver variability of particular boundaries to guide the 
SPFC-TD process.
Pathologic stage is generally viewed as more accurate, 
incorporating both any information available from clinical 
(pretreatment) staging and from the results of a surgical resec-
tion and pathologic examination of the tissues. Nevertheless, 
clinical staging is of more practical value, because this is when 
major decisions regarding treatment strategy must be made. 
Therefore, a high priority must be the ability to apply stage 
classification clinically and pathologically. Few articles have 
addressed clinical staging in thymoma15,16; ITMIG is develop-
ing a prospective imaging repository that can provide a basis 
for future validation of clinical staging proposals.
The stage classification should be applicable to all types 
of thymic malignancies. It seems likely that this will not be a 
major stumbling block. Compatibility with an existing system 
is desirable but of lower priority because of the lack of a wide-
spread, consistently applied system. The number of different 
systems and the variability in how the wording in these systems 
has been interpreted inherently limit backwards compatibility.
Prognosis has been widely used as a tool to separate T, 
N, and M classes and stage groups, and there is no question 
that this should be considered in the development of a thy-
mic stage classification system. Nevertheless, some aspects 
of prognosis need to be taken into account—both fundamen-
tal issues with the use of prognosis for classification and spe-
cific issues for thymic malignancies. First of all, prognosis 
is complex and multifactorial, reflecting many confounding 
factors and not just the impact of tumor characteristics per se 
(e.g., comorbidities, treatment received). This confounding 
cannot be easily disentangled, even with multivariate analy-
sis; only natural history data (no active treatment) in patients 
without comorbidities can provide information about 
the impact of the tumor characteristics themselves. In the 
IASLC lung cancer database, this confounding was appar-
ent in the marked variability of overall survival outcomes 
among different geographic regions, data sources, and other 
subgroups. This was indirectly accounted for during devel-
opment of the seventh edition of the lung cancer stage clas-
sification by requiring that a valid boundary between T, N, 
and M classes or stage groupings had to show differences 
in prognosis (not prognosis per se) that were consistent in 
terms of magnitude and direction within multiple subgroup 
analyses. Nevertheless, such subgroup analyses are more 
difficult to carry out in thymic malignancies because of the 
much more limited number of patients. A requirement of sta-
tistically significant differences within subgroups is unlikely 
to be able to be met.
Prognosis in thymic malignancies is also more difficult 
to assess because of the poor correlation between recurrence 
and death, in contrast to many other malignancies. Thus the 
influence of other factors, unrelated to the thymic malignancy, 
on overall survival is large. A better measure of the effect of 
anatomic extent of disease may be the recurrence rate,17 but 
data on this outcome and how it was assessed are more lim-
ited. In addition, longer-term outcomes is likely influenced by 
treatment received; little data are available on how much vari-
ability there has been among centers.18
The Process of Developing a Thymic 
Stage Classification System
The planned process for the SPFC-TD is to gather data 
that inform the stage classification from whatever sources 
are available. This includes assessment of prognosis in the 
SPFC-TD retrospective database, studies of intra- and interob-
server variability, and suggested factors in the publications of 
institutions or other organizations. These will be evaluated 
and synthesized according to the priorities stated above.
One analysis will be an assessment of how well the 
Masaoka stage classification performs in separating prognosti-
cally distinct groups. The fact that prognosis is confounded by 
nonanatomic disease-extent characteristics will be addressed 
by subgroup analysis, similar to what was done in the devel-
opment of the seventh edition of the lung cancer stage classi-
fication system. The two most important confounding factors 
are likely to be competing causes of death (e.g., comorbidi-
ties) and treatment given. To account for this, the analysis 
will include a specific focus on recurrence and on patients 
who underwent resection. Because the ability to differentiate 
between an R0 and R1 resection in the past is in question, this 
aspect will also be investigated.
Size is an appealing parameter to explore, because (at 
least one dimension) is usually available, there is some prece-
dent for prognostic significance, and it can be applied clinically 
and pathologically. Nevertheless, larger thymic malignancies 
are not round, raising issues about how size was and should be 
measured and how well pathologic measurements (assessed 
in planes dictated by the tumor shape) correlate with clinical 
measurements (typically based on the greatest dimension on a 
transverse computed tomography image).
Finally, as many factors as possible will be investi-
gated that can serve as T, N, and M descriptors (e.g., inva-
sion into specific mediastinal structures, pleural, or pericardial 
implants). To address the issue of prognostic confounding by 
TABLE 2.  Characteristics and Guiding Principles
Characteristics of a thymic stage classification system
The thymic stage classification should:
•  Describe anatomic extent of disease only
•  Apply to all types of thymic malignancies
•  Be a TNM-based system
Guiding principles for the development of a thymic stage classification 
system
The thymic stage classification should be:
•  Able to be consistently applied
•  Applicable to clinical staging
•  Applicable to thymoma, thymic carcinoma, and thymic carcinoid 
tumors
•  Able to separate patient groups by prognosis
•  Compatible with existing (e.g., Masaoka-Koga) stage classification 
systems
•  Simple and straightforward to understand
TNM, tumor, node, metastasis.
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nonanatomic disease-extent factors, a focus on recurrence and 
resected patients is needed as described above.
Because thymic malignancies are a rare disease, the 
available data have some limitations. It is anticipated that 
enough data will be available to provide a basis for a thought-
ful proposal. Nevertheless, it is also recognized that some 
aspects will be more empiric and will require further study. 
The initiation of the ITMIG prospective database, which con-
tains much more detail, will provide a solid basis for this. The 
development of a thymic stage classification system for the 
eighth edition of the stage classification represents only the 
beginning of an ongoing process.
Although the eighth edition is not scheduled for pub-
lication until 2016, the AJCC/UICC mandates that ITMIG/
IASLC completes its work in developing proposals in 2014. 
Assessment of outcomes for many thymic malignancies takes 
time with respect to overall survival; nevertheless, the median 
time to recurrence for stage ≥III is 3 to 4 years. This may allow 
some preliminary validation of a classification developed from 
the retrospective database against recurrence data in the pro-
spective database before the stage classification takes effect.
Prognostic Model
The initial focus of the SPFC-TD is clearly on develop-
ing proposals for classification of the anatomic extent of dis-
ease. Nevertheless, there is a need for a prognostic model for 
thymic malignancies, as is true for cancers in general. In some 
ways, this is more difficult in thymic malignancies because 
much less data are available, but in other ways, this facilitates 
development of a structure to build upon. Several ITMIG 
initiatives will help the development of a prognostic model, 
including the prospective database, the use of Bayesian analy-
sis, and development of adaptive models to guide treatment. 
This work will take some time, and therefore a prognostic 
model is not a planned deliverable together with the eighth 
edition of the stage classification.
CONCLUSION
Thymic malignancies are an orphan disease; one of 
the many things that hampers progress is the lack of a well-
defined stage classification system. ITMIG and IASLC have 
partnered in a formal, structured process to develop this 
for the next (eighth) edition of the stage classification. This 
involves an international committee of experts, creation of a 
large (by thymic standards) database, and careful analysis of 
data regarding multiple aspects that influence the definition of 
stage descriptors and grouping. This article outlines the status 
of this project and the process that is planned.
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